All looks good for Monday with a great article in this morning's Fin Review that says the Phase IIb trial of its apricitabine (ATC) drug has produced a better than hoped for results. Also speculates that Avexa will announce a capital raising of about $25 million. The journalist says that Avexa could be sitting on a pharmaceutical goldmine.